RISKS OF HYPOGLYCEMIC PHARMACOTHERAPY IN ELDERLY PATIENTS WITH NEUROLOGICAL AND PSYCHIATRIC DISORDERS

ABSTRAKT

Based on the results of the analysis of scientific studies by domestic and foreign authors over the past 5 years, a description and discussion of the possible risks of pharmacotherapy by various groups of sugar-lowering drugs for type 2 diabetes mellitus in elderly and senile patients with neurological and mental disorders is presented. The pharmacodynamic parameters of the main representatives of hypoglycemic agents are given, which make it possible to assess the safety of their use in geriatric patients. The requirements and principles of hypoglycemic pharmacotherapy in elderly patients are described to reduce the risks of adverse reactions. For elderly and senile patients with impaired central nervous system function in the treatment of type 2 diabetes, metformin is the hypoglycemic drug with the lowest risk of adverse reactions. There are prospects for the use of modern groups of sugar-lowering drugs, such as incretinomimetics and gliflozines. Sulfonylurea derivatives, glitazones and glinides are not indicated for the elderly.

Keywords: hypoglycemic agents, type 2 diabetes mellitus, geriatric patient, adverse drug reaction